Skip to main content
. Author manuscript; available in PMC: 2016 May 12.
Published in final edited form as: Oncogene. 2012 Apr 9;32(7):861–871. doi: 10.1038/onc.2012.105

Figure 4.

Figure 4

eIF4E suppression decreases breast tumor and lung metastasis burden by increased apoptosis in vivo. (a) sh4E.389 and shFLuc.1309-infected TM15 cells were injected into fat pads of nude mice and treated with DOX upon tumor onset. Tumor weights were documented at 40 days after detection by palpation. *P<0.005; **P = 0.02. (b) Pulmonary metastasis was quantitated 40 days after appearance of primary tumors. *P<0.001; **P = 0.02. (c) Representative immunohistological staining of eIF4E and GFP in a breast tumor (entire section) and lung metastatic (arrow) lesion of a DOX-treated mouse with either sh4E.389-infected or shFLuc.1309-infected TM15 cells. Bar, 0.2 mm. (d) Quantitation of TUNEL-positive cells of pulmonary metastasis and primary tumors from allografts of sh4E.389- and shFLuc.1309-infected TM15 cells; n = 3; *P<0.005. (e) Quantitation of Ki-67-positive cells from pulmonary metastasis and primary tumors from allografts of sh4E.389- and shFLuc.1309-infected TM15 cells; n = 3.